Clinical Trials Browser

Carcinoma, Neuroendocrine, Neuroendocrine Tumors, Small Cell Lung Carcinoma

Uveal Melanoma, Melanoma

Squamous Cell Carcinoma of Head and Neck, Oropharyngeal Neoplasms

Neoplasm Metastasis, Skin Neoplasms, Carcinoma, Merkel Cell

Adenocarcinoma, Carcinoma, Pancreatic Neoplasms

Kidney Neoplasms

Breast Neoplasms

Head and Neck Neoplasms

Carcinoma, Non-Small-Cell Lung

Brain Neoplasms, Melanoma

Carcinoma, Non-Small-Cell Lung

Diabetes Mellitus, Insulin-Dependent, 12, Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis, Recurrence

Prostatic Neoplasms

Salivary Gland Neoplasms

Carcinoma, Non-Small-Cell Lung

Meningeal Carcinomatosis

Microsatellite Unstable Colorectal Cancer

Carcinoma, Non-Small-Cell Lung

Fallopian Tube Neoplasms, Ovarian Neoplasms

Urinary Bladder Neoplasms, Melanoma

Colonic Neoplasms

Thyroid Neoplasms

Carcinoma, Non-Small-Cell Lung, Neoplasms

Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Neoplasm Metastasis

Uveal Melanoma

Carcinoma, Non-Small-Cell Lung

Leiomyosarcoma

Diabetes Mellitus, Insulin-Dependent, 12, Small Cell Lung Carcinoma

Carcinoma, Renal Cell

Adenocarcinoma, Carcinoma, Neoplasms, Pancreatic Neoplasms

Uveal Melanoma

Carcinoma, Non-Small-Cell Lung

Diabetes Mellitus, Insulin-Dependent, 12, Melanoma

Carcinoma, Non-Small-Cell Lung

Advanced Solid Tumors

Clinical Trials

Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors

Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma

Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma

Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma

A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma

Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma

Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer

Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)

NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer

Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity

An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent Meningioma

Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)

Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain

Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC

Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy

CheckMate 650

Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer

Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

NA_00092076

Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

Ipilimumab and Nivolumab in Leptomeningeal Metastases

CheckMate142

TOP1705

Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)

PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC

Nivolumab Plus Ipilimumab in Thyroid Cancer

Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)

Pembrolizumab and Ipilimumab After Prior Immunotherapy for Melanoma

Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia

Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 2

IMPACT

Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver

Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy

Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer

Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma

UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma

STIMULI

Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma

Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma

CheckMate 848

Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer

Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma

CheckMate 592

Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma

A Study of IMM-101 in Combination With Checkpoint Inhibitor Therapy in Advanced Melanoma

A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab

Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets

A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer

NIMBLe